A New Breakthrough in Ovarian Cancer Therapy: IOSE-80, SKOV-3 and OVCAR-8 in Ovarian Cancer study
Ovarian cancer (OC) is a common and highly malignant tumor of the female reproductive system, with the highest mortality rate among gynecological cancers. Although surgery combined with platinum-based chemotherapy is the standard treatment, drug resistance and high recurrence rates severely limit patient survival (5-year survival rate < 40%). The JAK/STAT3 signaling pathway has been confirmed as a key driver of OC progression and chemoresistance; however, existing JAK inhibitors suffer from severe side effects, including bone marrow suppression. Therefore, there is an urgent need to identify safe and effective novel inhibitors of the JAK/STAT3 pathway.Recently, a study published in Advanced Science employed large-scale screening and, for the first time, identified the natural pentacyclic triterpene saponin α-Hederin as a potent and selective dual inhibitor of JAK1/JAK2. This compound significantly suppressed OC progression in both cellular and animal models, exhibiting excellent in vivo safety and synergistic effects with cisplatin, thereby offering a highly promising drug candidate for OC therapy.
Advance your Ovarian cancer (OC) research with our IOSE-80 and SKOV-3 cell lines. Good viability and strict QC passed. Click to check>>IOSE-80, SKOV-3, OVCAR-8
1. Multi-Scale Screening: "Finding a Needle in a Haystack" Identifies the Star Molecule α-Hederin
The research team first confirmed, through bioinformatics analysis, that the IL-6/JAK/STAT3 signaling pathway is significantly activated in OC tissues, suggesting its potential as a therapeutic target.
Subsequently, they established a systematic drug discovery pipeline: structure-based virtual screening targeting JAK1 and JAK2 proteins was performed on a library containing 2,908 natural compounds, followed by experimental validation via cytotoxicity assays. Through this multi-step screening process, α-Hederin emerged as the top candidate.
(Workflow of structure-based virtual screening and validation)
α-Hederin exhibited a half-maximal effective concentration (EC50) of 6.05 μM against OC cells (SKOV-3), while showing no significant toxicity to normal ovarian epithelial cells (IOSE-80) even at concentrations as high as 60 μM, demonstrating a favorable therapeutic window.
2. Precision Targeting: α-Hederin Directly Binds and Inhibits JAK1/JAK2
Molecular docking simulations showed that α-Hederin binds tightly to the JH1 kinase domain (ATP-binding pocket) of JAK1 and JAK2, with binding free energies as low as -12.57 and -12.10 kcal mol⁻¹, respectively.
Experimental validation confirmed this direct interaction:
1. Microscale Thermophoresis (MST) measured the dissociation constants (Kd) for binding to JAK1 and JAK2 as 9.96 μM and 4.71 μM, respectively.
2. DARTS (Drug Affinity Responsive Target Stability) assays demonstrated that α-Hederin dose-dependently protected JAK1/JAK2 from protease degradation, providing direct evidence of target engagement within cells.
3. In vitro kinase assays confirmed that α-Hederin concentration-dependently inhibited the kinase activities of JAK1 and JAK2, consequently reducing their phosphorylation of STAT3.
Network pharmacology analysis further linked the action of α-Hederin to cancer-related pathways, including JAK/STAT signaling.
3. Potent Anti-Cancer Effects: Comprehensive Inhibition of Malignant OC Cell Behaviors
1. Inhibition of Proliferation and Cell Cycle Arrest
CCK-8, EdU, and colony formation assays consistently demonstrated that α-Hederin inhibits OC cell proliferation in a time- and dose-dependent manner, while barely affecting normal cells. It induced G0/G1 phase cell cycle arrest and downregulated the expression of cyclin D1 and CDK4.
2. Inhibition of Migration, Invasion, and the EMT Process
Wound healing and Transwell assays showed that α-Hederin significantly suppressed the migration and invasion abilities of OC cells. Concurrently, it reversed epithelial-mesenchymal transition (EMT), evidenced by upregulation of the epithelial marker E-cadherin and downregulation of the mesenchymal markers N-cadherin, Vimentin, and the transcription factor Snail.
3. Core Mechanism: Blockade of the JAK/STAT3 Signaling Axis
α-Hederin treatment markedly reduced the phosphorylation level of STAT3 at tyrosine residue 705 (p-STAT3 Y705) and prevented its nuclear translocation. The expression of its downstream pro-oncogenic target genes (e.g., MYC, CCND1, TWIST1) was subsequently downregulated.
4. In Vivo Validation: High-Efficacy Tumor Suppression with Excellent Safety Profile
In a subcutaneous xenograft model, α-Hederin significantly suppressed tumor growth, with efficacy comparable to cisplatin. However, its key advantage lies in its superior safety profile.
· No Systemic Toxicity: Mice body weights remained stable during treatment, whereas the cisplatin group exhibited significant weight loss.
· No Organ Damage: No pathological changes were observed in vital organs including the heart, liver, lung, and kidney; liver and kidney function markers remained normal.
· No Bone Marrow Suppression: Peripheral blood cell counts remained within normal ranges, avoiding a common side effect associated with existing JAK inhibitors.
In a lung metastasis model established via tail vein injection, α-Hederin treatment similarly resulted in a significant reduction in the formation of lung metastatic nodules.
5. Mechanistic Confirmation: STAT3 Reactivation Reverses the Effects of α-Hederin
To determine whether α-Hederin acts specifically through the JAK/STAT3 pathway, the study employed a "rescue experiment" using the STAT3 agonist Colivelin. The results showed that Colivelin could partially restore STAT3 phosphorylation that had been suppressed by α-Hederin, and consequently reverse the inhibitory effects of α-Hederin on cell proliferation, migration, invasion, and EMT.
In vivo, Colivelin also partially counteracted the tumor-suppressive effect of α-Hederin. These findings strongly confirm that the anti-OC action of α-Hederin is primarily dependent on its inhibition of the JAK/STAT3 signaling axis.
6. Clinical Potential: Synergy with Cisplatin and Overcoming Platinum Resistance
One of the most clinically translational findings of this study is the synergistic effect of α-Hederin with the standard chemotherapy drug cisplatin (CDDP).
1. Potent Synergy: Combination therapy exhibited significantly stronger anti-tumor effects than either monotherapy, both in vitro and in an orthotopic xenograft model.
2. Overcoming Drug Resistance: In established cisplatin-resistant OC cell lines, pre-treatment with a low dose of α-Hederin significantly restored the sensitivity of the tumor cells to cisplatin.
This suggests that α-Hederin may serve not only as a monotherapy but also potentially as a chemosensitizer to improve the efficacy of existing chemotherapy and reverse drug resistance.
Research Summary
This study systematically positions the natural compound α-Hederin as a novel, safe, and effective dual inhibitor of JAK1/JAK2, which suppresses OC progression through multiple mechanisms via blockade of the JAK/STAT3 pathway. The publication of this work in a high-impact journal like Advanced Science can be attributed to its comprehensive, rigorous, and highly translatable research framework:
1. Innovative Starting Point: The "discovery" of the lead compound was achieved through a scientific approach integrating bioinformatics, large-scale virtual screening, and experimental validation, rather than by serendipity.
2. In-Depth Mechanistic Elucidation: The study not only observed phenotypes (tumor suppression, anti-metastasis) but also systematically unraveled the precise target and molecular mechanism, progressing from molecular docking, direct binding (MST, DARTS), and kinase activity inhibition to downstream signaling and gene regulation.
3. Comprehensive In Vivo Validation: The efficacy was validated using multiple models, including in vitro cell assays, subcutaneous/orthotopic xenografts, and a lung metastasis model, providing robust and multi-faceted data.
4. Outstanding Safety and Synergy Advantages: The study clearly demonstrated a superior safety profile compared to synthetic JAK inhibitors and highlighted its potential to synergize with first-line chemotherapy and overcome drug resistance, directly addressing key clinical challenges.
5. Rigorous Mechanistic Confirmation: Through genetic knockdown and agonist rescue experiments, the study strongly confirmed the core signaling axis, making the conclusions highly reliable.
This research provides compelling preclinical evidence for developing low-toxicity targeted therapies based on natural products, positioning α-Hederin as a promising new star in the field of ovarian cancer therapy.
Reference:
